Sutro Biopharma
STRO
114 hedge funds and large institutions have $241M invested in Sutro Biopharma in 2022 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 25 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
0.84% more ownership
Funds ownership: 8.98% → 9.82% (+0.84%)
0% more funds holding
Funds holding: 114 → 114 (0)
30% less capital invested
Capital invested by funds: $342M → $241M (-$101M)
30% less call options, than puts
Call options by funds: $727K | Put options by funds: $1.03M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11M |
| 2 |
Holocene Advisors
New York
|
+$5.44M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$5.1M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.03M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$4.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$13.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 3 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$3.21M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.37M |
| 5 |
Rafferty Asset Management
New York
|
-$1.35M |
STRO Hedge Fund Activity: Q2 2022 in Review
114 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2022, worth a combined $241M — down 30% from $342M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new STRO positions and 25 closed out — a net gain of 3 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Millennium Management, adding an estimated $11M. The largest seller was First Light Asset Management, exiting entirely with an estimated $13.7M sold.
- 114 institutional investors held Sutro Biopharma (STRO) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $241M of Sutro Biopharma stock for Q2 2022, down 30% quarter-over-quarter.
- 28 funds opened new Sutro Biopharma positions in Q2 2022 and 25 closed out, a net change of +3 holders.
- The largest Sutro Biopharma buyer in Q2 2022 was Millennium Management, an estimated $11M added.
- The largest Sutro Biopharma seller in Q2 2022 was First Light Asset Management, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2022.